At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 76 enrolled
Drug / intervention
Telotristat etiprate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
In Brief
A Phase 3 clinical trial evaluating Telotristat etiprate and Placebo for Carcinoid Syndrome. Completed, enrolled 76 participants across 50 sites in 11 countries.
Detailed Summary
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Syndrome
CountriesAustralia, Belgium, Canada, France, Germany, Israel, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMar 2014
Primary CompletionMar 2016
TodayJul 2026
First PostedFeb 14, 2014
Enrollment StartMar 11, 2014
Primary CompletionMar 29, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.4 years ago
Interventions
Telotristat etipratedrug
Telotristat etiprate tablets
Placebodrug
Placebo-matching telotristat etiprate tablets